Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2013

May 14, 2013

151_ip_2013-05-14_3d0f470a-b333-4742-9cd3-e6fca24fa2aa.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Q1 2013 Driving Inn ovation Efficiency

Forward-looking s statements

Information set forth in this presen forward-looking statements, whi number of risks and uncertainties. looking statements contained herein judgement of Evotec as of the presentation. Such forward-looki are neither promises nor guaran subject to a variety of risks and many of which are beyond our cont tation containsich involve aThe forward. forwardn represent the date of thising statements ntees, but are d uncertainties trol, and which

could cause actual results to differ materially from those contemplated in these forward looking statements We expressly disclaim any statements.obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on uncertainties, which any such statement is based based.

Welcome from theeEvotec management team

Q1 2013

Agenda

Highlights Q1 2013

  • Driving Innovation Efficie ency
  • Financial Performance &Outlook

1

2

3

Strong gp strategic p efficiency osition – driving innovation

State of play – Q1 highligh hts

  • Revenues of € 17.1 m (2012: € 20.1 m) does not include milestones in Q1 2013
  • Revenues excluding milestones increased by 5% % compared to the first quarter of 2012
  • € 2.7 m operating loss due to absence of milesto ne payments

EVT Execute – Investing in strategic expansion

  • Th t i f d di lli Three-year extension of drug discovery alliance w ith G t h1) with
  • Important strategic expansion of compound mana Genentech1)agement capability to the East Coast, USA1)

EVT Integrate Increase in revenues driven by Integrate – long-term alliances

All integrated alliances achieved progress within t Evotec's integrated deals, e.g. Bayer, UCB their projects. Growth in revenues mainly driven by

EVT Innovate – Alliances and investments to acccelerate innovation strategy

  • Oncology research collaboration with Belfer1)
  • Broad open innovation alliance started with Yale 4
  • New hormone identified to treat diabetes as part of Evotec's CureBetainitiative1)
  • Co-development agreement with Apeiron AG
  • Significant clinical data points ahead in 2013/201 4/2015

Solid start, expect support positive o ted milestones in H2 outlook for 2013

Financial summary Q1 20 13

R
h
t
e
e
n
e
g
r
o
v
u
w
i
d
d
i
n
r
g
s
c
o
e
r
u
v
y
l
f
b
t
t
p
a
o
r
m
n
o
u
i
l
t
m
e
s
o
n
e
t
p
a
y
m
e
n
s		 R
d
d
d
d
b
1
%
€
1
1
1
1
l
d
i
i
i
l
l
E
'
5
t
7
7
t
t
t
e
e
n
e
s
e
e
c
c
r
r
e
e
a
a
s
s
e
e
o
m
e
c
n
g
m
m
e
e
s
s
o
o
n
n
e
e
s
s
o
e
c
s
v
u
y
y
;
x
u
v

,
l
d
h
i
d
b
5
%
h
i
d
t
r
e
v
e
n
u
e
s
w
o
u
a
v
e
n
c
c
r
e
a
s
e
y
o
v
e
r
e
s
a
m
e
p
e
r
o
S
€
t
l
i
i
d
i
t
i
t
i
t
6
0
4
r
o
n
g
q
u
y
p
o
s
o
n
a
a
m

%
%
H
i
h
d
t
b
l
i
t
t
i
t
6
6
7
7
3
3
g
a
n
s
a
e
e
q
r
r
a
a
a
o
a
u
y
f
f
I
I
t
t
t
t
n
n
v
e
e
s
s
m
m
e
e
n
n
s
s
o
o
r
r
C
F
i
t
i
l
r
s
n
a
s
s
-
-
t
t
a
r
g
e
s		 &
f
€
2
3
f
f
I
d
R
D
i
t
d
i
t
h
i
l
d
n
c
r
e
a
s
e
e
p
e
n
s
e
e
s
o
m
n
e
s
e
n
e
e
s
o
x
v

C
X
i
i
i
i
G
P
C
R
R
d
k
i
l
f
h
l
i
t
t
t
t
u
r
e
n
a
v
e
s
a
n
n
a
s
e
p
a
o
r
m
e
c
n
o
o
g
e
s
,
G
i
d
u
a
n
c
e
f
f
2
0
1
3
o
r
f
i
d
c
o
n
r
m
e		 S
t
d
b
k
d
i
l
t
t
i
t
i
i
H
2
i
d
i
t
r
o
n
g
o
r
e
r
o
o
a
n
m
m
e
s
o
n
e
o
p
p
o
r
u
n
e
s
n
n
c
a
e

f
€
9
0
1
0
0
f
2
0
1
3
r
e
v
e
n
u
e
s
o
m
o
r
-
I
i
f
l
l
f
i
b
i
l
i
d
h
t
t
t
t
t
n
c
r
e
a
s
n
g
u
y
e
a
r
p
r
o
a
y
u
e
o
r
e
v
e
n
u
e
g
r
o
w

d
t
d
i
l
t
t
a
n
e
p
e
c
e
m
e
s
o
n
e
p
a
m
e
n
s
x
y

Agenda

  • Highlights Q1 2013
  • Driving Innovation Effi ciency
  • Financial Performance &Outlook

Addressing the inn novation challenge

Innovation Efficiency

Solid growth in Q1 So d g o t Q of stand-alone Exe1 20130 3ecute business

Comprehensive drug disco overy platform – "EVO Apps"

Strong Med Chem Execute business services driving

Key Execute/Integrate act tivities in Q1

E
A
i
i
t
t
t
e
c
e
c
x
u
v
y		 P
t
a
r
n
e
r
s		 T
i
l
d
l
t
p
c
a
e
a
e
r
m
s
y
C
M
d
i
i
l
h
i
t
e
c
n
a
e
m
s
r
y		 C
C
H
D
I,
U
B
B
B
I,
E
i
a
y
e
r,
p
z
y
m
e
,
,
A
t
i
B
i
t
h
c
v
e
o
e
c
c		 1
)
F
T
E
t
p
a
y
m
e
n
s
,
i
l
t
l
t
i
m
e
s
o
n
e
s
r
o
y
a
e
s
,
I
i
i
i
t
n
v
r
o
o
n
v
v
,
h
l
p
a
r
m
a
c
o
o
g
y		 G
h
C
H
D
I,
O
B
t
e
n
e
n
e
c
n
o
a
e
r
y
,
,		 F
T
E
t
t
p
p
a
a
m
m
e
e
n
n
s
s
y
y
,
i
l
l
i
t
t
m
e
s
o
n
e
s
r
o
a
e
s
y
,
S
i
d
c
r
e
e
n
n
g
a
n
l
l
f
i
l
i
m
o
e
c
a
r
p
r
o
n
g
u		 T
P
h
C
b
i
E
i
5
t,
o
p
a
r
m
m
a
s
p
m
e
u
z
y
,
,
O
E
B
i
h
t
t
n
o
n
e
r
g
g
e
n
o
e
c
y
,
,		 2
)
F
F
S
C
d
o
m
p
o
u
n
M
t
a
n
a
g
e
m
e
n		 C
N
I
H
E
P
A
N
I
,
,		 S
F
F
P
t
i
r
o
e
o
m
c
s		 S
J
D
i
i
h
i
k
a
n
s
s
e
n
a
a
c
a
n
y
o
,
,
B
i
t
h
o
e
c		 S
F
F
F
T
E
,
,
i
l
t
m
e
s
o
n
e
s
P
i
P
d
i
d
t
t
r
o
e
n
r
o
c
o
n
a
n
u
C
l
l
C
l
S
i
t
e
r
e
e
r
c
e
s
u
u
v		 T
5
P
h
B
i
h
t
o
p
a
r
m
m
a
o
e
c
,		 F
F
S

Growth driven by high-quality

EVT Execute strategy 2013 3

Expand offering for xpand customer solutions

1

Expand footprint wit closer to our custom 2 th services even mers, e.g. US East Coast

more complete

Further improve gro 3 profitability oss margins and

Building an even s of partnerships strong p erortfolio

EVT Integrate strategy 20 13

Further expansion of one more new strateg 1 f portfolio with at least portfolio least gic multi-target alliance

Increase amount of min ongoing alliances 2 milestone achievements

Expand customer rea 3 customer and mid-sized Pharm ach to even more biotech ma customers

Systematic unbias ystematic, and comprehensiv sedve approach

"EVT Integrate & Innovat e" disease focus

  • Driving existing product candidates to expand "Pharma pipeline without risk"
  • Offering whole ology infrastructure and discovery solutions
  • Disease and target track record leveraged across i di tiindications

Significant p g ro re in the next 24 monss expected nths

Clinical-stage pipeline

D
C
d
i
d
t
r
u
g
a
n
a
e		 P
(
S
f
h
i
)
t
t
t
t
a
r
n
e
r
a
r
o
p
a
r
n
e
r
s
p		 P
D
C		 P
h
I
a
s
e		 P
h
I
I
a
s
e		 P
h
I
I
I
a
s
e		 S
t
t
a
u
s
®
®
D
D
i
i
P
P
2
2
7
7
7
7
a
e
p
(
)
D
i
b
t
a
e
e
s		 /
(
2
0
0
)
T
E
V
A
A
d
d
7
n
r
o
m
e
a		 d
n
2
P
h
I
I
I
i
t
t
a
s
e
r
e
c
r
u
m
e
n
l
d
l
t
t
d
d
c
o
s
e
r
e
s
u
s
e
x
p
e
c
e
e
n
,
f
(
)
2
0
1
4
o
e
E
V
T
3
0
2
(
A
l
h
i
's
z
e
m
e
r
)
d
i
s
e
a
s
e		 R
h
(
(
2
0
1
1
)
)
o
c
e		 S
f
P
h
I
I,
l
t
t
t
a
r
o
a
s
e
r
e
s
u
s
d
2
0
1
(
)
t
5
e
x
p
e
c
e
e
E
V
T
1
0
0
i
s
e
r
e
s
(
D
i
)
e
p
r
e
s
s
o
n		 J
(
2
0
1
2
)
a
n
s
s
e
n		 P
t
d
i
D
2
0
1
2
a
r
n
e
r
e
n
e
c
,
f
P
h
I
I
d
i
t
t
s
a
r
o
a
s
e
u
r
n
g
2
0
1
3
/
2
0
1
4
(
)
e
E
V
T
2
0
1
(
I
i
)
n
s
o
m
n
a		 J
i
X
i
(
2
0
1
0
)
n
g
n		 I
A
i
l
2
0
1
3,
l
n
p
r
a
p
p
r
o
a
v
i
d
f
C
D
E
t
r
e
c
e
v
e
r
o
m
o
l
i
i
l
i
l
t
c
o
m
m
e
n
c
e
c
n
c
a
r
a
s
S
t
i
i
o
m
a
o
p
r
m
(
A
l
)
c
r
o
m
e
g
a
y
…		 A
i
(
2
0
1
2
)
s
p
r
e
o		 P
t
i
a
r
n
e
r
n
g
E
V
T
4
0
1
(
I
f
l
t
i
)
n
a
m
m
a
o
n		 C
(
)
b
2
0
1
2
o
n
a		 C
P
h
I
I
t
t
i
h
i
a
s
e
s
a
r
n
n
a
V
i
a
r
o
s
u		 V
i
a
r
o
s
u		 C
l
i
i
l
t
t
n
c
a
s
a
r
s

Broad first-in-class diabetes product pipeline

Diabetes pipeline overview w

(
)
M
l
l
o
e
c
u
e
s		 I
d
i
t
i
n
c
a
o
n
(
)
h
i
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
t
e
x
i
l
t
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
®
D
i
P
2
7
7
a
e
p		 T
1
d
i
b
t
p
e
a
e
e
s
y
(
i
d
l
i
)
t
m
m
u
n
o
m
o
u
a
o
n		 d
2
P
h
I
I
I
n
a
s
e
e
i
t
t
r
e
c
r
u
m
e
e
n
l
d
c
o
s
e		 F
i
l
P
h
I
I
I
n
a
a
s
e
d
t
a
a		 €
A
4
0
i
l
t
l
t
i
p
p
r
o
m
m
e
s
o
n
e
s,
r
o
a
e
s
x.
y
;
€
t
t
i
l
k
t
5
0
0
p
o
e
n
a
m
a
r
e
a
p
p
r
o
m
x.
E
V
T
7
7
0		 T
1
d
2
d
i
b
t
y
p
e
a
n
a
e
e
s
(
b
t
l
l
e
a
c
e
)
t
i
r
e
g
e
n
e
r
a
o
n		 P
l
i
i
l
r
e-
c
n
c
c
a		 N
D		 H
i
h
i
h
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
€
2
3
7
i
l
t
/
d
t
m
m
e
s
o
n
e
s
p
r
o
c
u
;
f
i
i
i
t
l
t
i
s
g
n
c
a
n
r
o
a
e
s
y
A
L
M		 T
1
d
2
d
i
b
t
p
e
a
n
a
e
e
s
y
(
b
t
l
l
e
a
c
e
i
)
t
r
e
g
e
n
e
r
a
o
n		 P
l
i
i
l
r
e-
c
n
c
c
a		 N
D		 H
i
h
i
h
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
m
e
n
s
y
€
1
8
3
/
i
l
t
d
t
m
m
e
s
o
n
e
s
p
r
o
u
c
;
i
i
f
i
l
i
t
t
s
g
n
c
a
n
r
o
y
a
e
s
E
V
T
0
0
7		 T
T
1
1
d
d
2
2
d
d
i
i
b
b
t
t
y
p
e
a
n
a
e
e
s
(
b
l
l
t
e
a
c
e
i
)
t
r
e
g
e
n
e
r
a
o
n		 P
P
l
l
i
i
i
i
l
r
e-
c
n
c
c
a		 N
D		 H
H
i
i
h
h
i
i
h
h
t
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
€
2
5
4
i
l
t
m
m
e
s
o
n
e
s
S
i
i
f
i
t
l
t
i
g
n
c
a
n
r
o
a
e
s
y
C
B
t
e
a
u
r
e
C
/
B
0
0
2
1
+
t
h
o
e
r
s		 T
1
d
2
d
i
b
t
y
p
e
a
n
a
e
e
s
(
b
t
l
l
e
a
c
e
)
t
i
r
e
g
e
n
e
r
a
o
n		 P
l
i
i
l
c
a
r
e-
c
n
c		 N
D		 H
i
h
i
h
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
\$
3
0
0
i
l
/
d
i
i
f
i
t
t
t
m
m
e
s
o
n
e
s
p
r
o
u
c
;
s
g
n
c
a
n
l
i
t
r
o
y
a
e
s

Alzheimer's diseasleading CNS pipel se late-stag pp y e opportunity ine

Neurology pipeline overvi iew

(
)
M
l
l
o
e
c
u
e
s		 I
d
i
t
i
n
c
a
o
n
(
)
h
i
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
t
a
u
s		 N
t
i
l
t
e
x
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
E
V
T
3
0
2		 's
A
l
h
i
e
m
e
r
z
D
i
(
M
A
O
B
)
s
e
a
s
e
-		 P
h
I
I
b
a
s
e		 C
f
l
t
i
P
h
o
m
p
e
o
n
o
a
s
e
I
I,
P
h
I
I
I
t
t
a
s
e
s
a
r		 \$
8
2
0
i
l
t
m
m
e
s
o
n
e
s
S
i
i
f
i
l
i
t
t
g
n
c
a
n
r
o
y
a
e
s
E
V
T
1
0
0
i
s
e
r
e
s		 (
)
D
i
N
R
2
B
e
p
r
e
s
s
o
n		 /
P
h
I
I
a
s
e
l
i
i
l
p
r
e
c
n
c
a		 C
f
f
f
i
t
i
o
n
r
m
a
o
n
o
o
/
l
i
i
l
t
d
p
r
e-
c
n
c
a
s
u
y
P
h
I
/
I
I
t
t
a
s
e
s
a
r		 \$
1
6
0
i
l
t
m
m
e
s
o
n
e
s
S
f
i
i
i
t
l
t
i
g
n
c
a
n
r
o
y
a
e
s
E
V
T
2
0
1		 I
i
n
s
o
m
n
a		 P
h
I
I
a
s
e		 S
l
i
i
l
i
l
t
t
t
a
r
c
n
c
a
r
a
s		 M
M
i
i
l
l
l
i
t
t
t
e
e
s
s
o
o
n
n
e
e
s,
s
r
o
y
a
e
s
V
i
a
r
o
u
s		 H
t
i
t
u
n
n
g
o
n
D
i
s
e
a
s
e		 T
t
l
i
d
t
i
a
r
g
g
e
v
a
a
o
n		 N
A		 R
h
t
e
s
e
a
r
c
p
a
y
m
e
n
s
S
C
f
A
I
i
l
a
m
y		 M
l
t
i
l
l
i
p
e
s
c
e
r
o
s
s
u		 /
B
M
B
F
d
i
l
d
P
h
u
n
s
c
o
s
e
a
r
m
a		 L
d
d
t
i
e
a
g
e
n
e
r
a
o
n		 L
d
t
t
e
a
s
a
s
u		 N
D

Strong portfolio an novel pain and infl nd p p artnerships for lammation targets

Pain and inflammation pip peline overview

M
l
l
(
)
o
e
c
u
e
s		 I
d
i
t
i
n
c
a
o
n
(
h
i
)
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
i
l
t
t
e
x
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
E
V
T
4
0
1		 I
f
l
i
t
n
a
m
m
a
o
n
(
P
2
X
7
i
h
i
b
i
t
n
o
n		 ) P
h
I
/
I
I
a
s
e		 P
h
I
I
t
t
a
s
e
s
a
r		 €
A
6
0
i
l
t
l
t
i
p
p
r
o
x.
m
m
e
s
o
n
e
s,
r
o
y
a
e
s
V
i
a
r
o
u
s		 E
d
t
i
i
n
o
m
e
r
o
s
s		 P
l
i
i
l
r
e-
c
n
c
a		 P
l
i
i
l
r
e-
c
n
c
a
d
i
d
t
c
a
n
a
e		 U
f
€
1
2
l
l
t
t
t
t
p
r
o
n
m
;
o
a
v
a
u
e
u
p
o
a
p
p
r
o
x.
€
8
0
l
i
5
t
m
;
r
o
y
a
e
s
V
i
a
r
o
u
s		 /
V
i
P
i
a
r
o
u
s
a
n		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I
t
t
a
s
e
s
a
r		 R
h
P
t
i
l
t
l
t
i
e
s
e
a
r
c
a
y
m
e
n
s,
m
e
s
o
n
e
s,
r
o
y
a
e
s
V
i
a
r
o
u
s		 I
I
f
f
l
l
i
i
t
t
n
a
m
m
a
o
n		 P
l
i
i
l
r
e-
c
n
c
a		 P
P
h
h
I
I
t
t
t
t
a
s
e
s
a
r		 H
H
i
i
h
h
i
i
h
h
t
t
g
m
a
r
g
n
r
e
s
e
a
r
c
p
a
y
m
e
n
s
€
1
8
3
i
l
/
d
t
t
m
m
e
s
o
n
e
s
p
r
o
u
c
S
f
i
i
i
t
l
t
i
g
n
c
a
n
r
o
a
e
s
y
U
d
i
l
d
n
s
c
o
s
e		 /
V
i
P
i
a
r
o
s
a
n
u		 P
l
i
i
l
r
e-
c
n
c
a		 S
f
C
l
P
c
c
e
s
s
o
u
u		 R
h
t
t
i
i
l
l
t
t
l
t
i
e
s
e
a
r
c
p
p
a
a
m
m
e
e
n
n
s,
s
m
m
e
e
s
s
o
o
n
n
e
e
s
s,
r
o
a
e
s
y
y
y

BI alliance leads p pipeline of oncology targets

Oncology pipeline overvie w

M
l
l
(
)
o
e
c
u
e
s		 I
d
i
i
t
n
c
a
o
n
(
h
i
)
m
e
c
a
n
s
m		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
i
l
t
t
e
x
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
D
G
3
1
3
7		 A
l
/
N
E
T
c
r
o
m
e
g
a
y		 P
h
I
I
a
s
e
a		 P
h
I
I
d
i
t
a
s
e
a
a
n
l
a
c
r
o
m
e
g
a
y		 C
l
i
f
t
o
n
s
u
n
g
e
e
s
R
l
i
t
o
y
a
e
s
V
i
a
r
o
s
u		 V
i
a
r
o
s
u		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I,
F
i
t
i
a
s
e
r
s
n
m
a
n		 R
h
t
e
s
e
a
r
c
p
a
m
e
n
s
y
M
i
l
t
e
s
o
n
e
s
R
l
i
t
o
y
a
e
s
P
h
t
a
w
a
y
s
c
r
e
e
n		 C
b
l-
B
h
t
p
a
w
a
y		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
a
r
m
a
h
i
t
p
a
r
n
e
r
s
p		 S
h
d
h
t
a
r
e
r
e
s
e
a
r
c
c
o
s
s
M
i
l
t
e
s
o
n
e
s
R
l
i
t
o
y
a
e
s
E
i
i
i
p
g
e
n
o
m
c
s
t
t
a
r
g
e
s		 V
V
i
i
a
r
o
u
s		 P
P
l
l
i
i
i
i
l
l
r
e-
c
n
c
a		 P
h
a
r
m
a
t
h
i
p
a
r
n
e
r
s
p		 N
A
PA
GE
17

CureBeta – A world without innjectable insulin?

Harvard /Evotec partnersh hip

Betatrophin: A Hormone that Controls Pancreaticβ Cell Proliferation

Authors

Peng Yi, Ji-Sun Park, Douglas A. Melton Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Howard Hughes Medical Institute, Harvard University

Highlights

  • Betatrophin is a secreted protein expressed in liver and fat
  • Betatrophin specifically stimulates pancreatic β cell replication
  • Increase in β cell replication/mass impro es improves glycemic control

Expression of betatrophin1) in mouse liver strongly stimulates beta cell replication

18 1) Betatrophin overexpressing liver cells secrete the protein but not GFP plasmid DNA n into the bloodstream, leading to increased circulating Betatrophin levels in animals injected with Betatrophin

Open innovation w with a commercial outlet

Yale/Evotec partnership

Pioneering partner inhibitors of epige rship p to develop enetic targets

DFCI, Belfer and Evotec co ollaboration

First-in-class prod duct candidates

EVT Innovate strategy 201 13

Start of additional cli existing alliances wit 1 nical trials within thin the next 18 months

2

Commercialise one C Cure Xinitiative

Initiate 3-5 more Cure 3 3 5 programmes eX/ Target X

Agenda

  • Highlights Q1 2013
  • Driving Innovation Efficie ency
  • Financial Performance & Outlook

Decline in revenueno milestones comes due to mpared with previous years

Revenues & gross margin Q1

Clear investment ffocus for first-in-class innovation

Overview R&D and SG&AQ1

in €m

Op g erating result re higher R&D expen eflects lack of milestones and nses

Operating result and net r result Q1

in € m

Focused R&D inveestments accelerate strategy

Key financials Q1: Conden nsed profit & loss statement (IFRS)

i
€
n
m
Q
1
2
0
1
1
2		 Q
1
2
0
1
3
A
t
l
c
u
a
R
e
e
n
e
s
v
u		 2
0
1		 1
7
1
G
i
r
o
s
s
m
a
r
g
n		 %
%
3
2
5		 %
2
6
1
&
R
D
e
x
p
e
n
s
e
s
 1
9		 2
3
S
G
&
A
e
p
e
n
s
e
s
x
 4
4		 3
9
A
i
i
t
t
m
o
r
s
a
o
n
 0
5		 0
9
O
t
h
t
i
t
e
r
o
p
e
r
a
n
g
e
x
p
e
n
s
e
s
n
e

,		 1
)
0
9		 0
0
O
i
i
(
l
)
t
p
e
r
a
n
g
n
c
o
m
e
o
s
s		 (
1
3
)		 (
(
2
2
)
)
7
7
N
i
(
l
)
t
e
n
c
o
m
e
o
s
s		 (
2
0
)		 (
2
9
)

Excluding milestones, revenues would have increased by 5% and operating loss would have improved compared to the prior year period

26 1) Including fair value adjustment in the context of the con planned under utilisation of € 0.6 m ntingent consideration (earn-out Develogen) of € 0.3 m and parallel rental in Hamburg and the resulting

FY guidance confi rmed

Business overview 2013

i
n		 € m
Q
1
2
0
1
2		 Q
1
2
0
1
3		 ∆
Q
1
Q
1
–		 F
Y
G
i
d
a
n
c
e
u
2
0
1
3		 F
Y
2
0
1
2
R
e
v
e
n
u
e
s		 2
0
1		 1
7
1		 %
1
5
-		 9
0
1
0
0
-		 8
7
3
O
i
l
t
t
p
e
r
a
n
g
r
e
s
u		 (
1
3
)		 (
2
)
7		 I
d
m
p
r
o
e
v
2
0
1
2
o
e
r
v		 1
4
&
U
t
d
R
D
n
p
a
r
n
e
r
e
e
p
e
n
s
e
s
x		 (
)
1
9		 (
)
2
3		 %
2
2
+		 1
0
a
p
p
r
o
x		 8
3
L
i
i
d
i
t
t
i
d
q
u
y
a
p
e
r
o
d
e
n		 1
5
7		 6
0
4		 6
%
+		 1
)
6
0
>		 6
4
2

Strong news flow to come

Outlook and next steps for r 2013 ff

Key milestones for 2013
1
  • Revenue growth and inc creasing gross margin
  • EVT Execute Expansion success of ex xisting alliances
  • Significant long-term dea als with big and mid-sized Pharma and Biotech

At least 1 significant new Accelerated pre-clinical/ 2 EVT Integrate w integrated technology/disease alliance /clinical milestones

3EVT Innovate

  • Strong progress in produ uct development partnerships
  • Expansion of network of f academic alliances
  • Partnering of one pre-cli nical asset/development programme

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
AGM Information 2026
May 7
Interim / Quarterly Report 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Major Shareholding Notification 2026
May 5
View all filings →